Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.

Zhang F, LingHu R, Zhan X, Li R, Feng F, Gao X, Zhao L, Yang J.

Oncotarget. 2017 May 24;8(45):80020-80028. doi: 10.18632/oncotarget.18145. eCollection 2017 Oct 3.

2.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.

3.

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.

Knerr S, Hu EY, Zeliadt SB.

EGEMS (Wash DC). 2017 Mar 13;5(1):1269. doi: 10.13063/2327-9214.1269. eCollection 2017.

4.

Can Appealing to Patient Altruism Reduce Overuse of Health Care Services? An Experimental Survey.

Riggs KR, Ubel PA, Saloner B.

J Gen Intern Med. 2017 Jul;32(7):732-738. doi: 10.1007/s11606-017-4002-5. Epub 2017 Feb 2.

PMID:
28155043
5.

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.

Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A, Figueredo J, Tzivelekis S, Garcia J.

Support Care Cancer. 2016 Jun;24(6):2481-90. doi: 10.1007/s00520-015-3039-4. Epub 2015 Dec 15.

6.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

Kent EE, Mitchell SA, Castro KM, DeWalt DA, Kaluzny AD, Hautala JA, Grad O, Ballard RM, McCaskill-Stevens WJ, Kramer BS, Clauser SB.

J Clin Oncol. 2015 Aug 20;33(24):2705-11. doi: 10.1200/JCO.2014.60.6210. Epub 2015 Jul 20.

7.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.

Ann Oncol. 2015 Sep;26(9):1948-53. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28.

8.

Cancer care burden: aiming at the Achilles heel.

Ahmed S, Shahid RK, Gesy K.

Curr Oncol. 2015 Jun;22(3):e134-8. doi: 10.3747/co.22.2252. No abstract available.

9.

G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.

Barnes G, Pathak A, Schwartzberg L.

Cancer Med. 2014 Dec;3(6):1477-84. doi: 10.1002/cam4.344. Epub 2014 Nov 20. Review.

11.

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.

Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata N.

J Gynecol Oncol. 2014 Apr;25(2):124-9. doi: 10.3802/jgo.2014.25.2.124. Epub 2014 Apr 9.

12.

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.

Rigacci L, Puccini B, Kovalchuk S, Fabbri E, Bonizzoni E, Perrone T, Bosi A.

Support Care Cancer. 2014 Sep;22(9):2557-61. doi: 10.1007/s00520-014-2237-9. Epub 2014 Apr 17.

13.

Study design: two long-term observational studies of the biosimilar filgrastim Nivestimâ„¢ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C.

BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.

14.

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.

Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J.

Support Care Cancer. 2014 Mar;22(3):667-77. doi: 10.1007/s00520-013-2021-2. Epub 2013 Oct 24.

15.

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Waters GE, Corrigan P, Gatesman M, Smith TJ.

J Oncol Pract. 2013 Jul;9(4):203-6. doi: 10.1200/JOP.2012.000662. Epub 2012 Nov 6. Review.

16.

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

Strassels SA, Dickson M, Norris LB, Bennett CL.

J Natl Cancer Inst. 2013 Aug 7;105(15):1072-3. doi: 10.1093/jnci/djt198. Epub 2013 Jul 19. No abstract available.

17.

Colony-stimulating factors for febrile neutropenia during cancer therapy.

Bennett CL, Djulbegovic B, Norris LB, Armitage JO.

N Engl J Med. 2013 Mar 21;368(12):1131-9. doi: 10.1056/NEJMct1210890. Review. No abstract available. Erratum in: N Engl J Med. 2013 Jul 18;369(3):293. Dosage error in article text.

18.

Neutropenia and G-CSF in lymphoproliferative diseases.

Ria R, Reale A, Moschetta M, Dammacco F, Vacca A.

Hematology. 2013 May;18(3):131-7. doi: 10.1179/1607845412Y.0000000049. Epub 2012 Nov 19.

19.

Medical oncologists' perceptions of financial incentives in cancer care.

Malin JL, Weeks JC, Potosky AL, Hornbrook MC, Keating NL.

J Clin Oncol. 2013 Feb 10;31(5):530-5. doi: 10.1200/JCO.2012.43.6063. Epub 2012 Dec 26.

20.

A way forward on the medically appropriate use of white cell growth factors.

Smith TJ, Hillner BE.

J Clin Oncol. 2012 May 10;30(14):1584-7. doi: 10.1200/JCO.2011.39.9980. Epub 2012 Feb 27. Review. No abstract available.

Supplemental Content

Support Center